Personalized medicine for metastatic breast cancer

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 615-624

  Chen, Tom Wei Wu ^a   Bedard, Philippe L ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

metastatic breast cancer; next generation sequencing; personalized medicine; targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; APITOLISIB; AZD 4547; AZD 5363; BGJ 398; BRIVANIB; BUPARLISIB; BYL 719; CABOZANTINIB; CARBOPLATIN; COBIMETINIB; COPANLISIB; DOVITINIB; EVEROLIMUS; EXEMESTANE; FORETINIB; FULVESTRANT; GDC 0032; GDC 0068; INC 280; INK 1117; LEE 011; LETROZOLE; LY 2835219; MK 1775; NERATINIB; NIRAPARIB; OLAPARIB; ONARTUZUMAB; PACLITAXEL; PALBOCICLIB; PICTILISIB; RABEPRAZOLE; TEMOZOLOMIDE; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; XL 147; XL 765;

ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL METABOLISM; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA REPAIR; DNA SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; MELANOMA; OVARY CARCINOMA; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA REPAIR; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; POLY(ADP-RIBOSE) POLYMERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84885430479     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000015     Document Type: Review

References (67)

1. Geiger S, Cnossen JA, Horster S, et al. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005. Anticancer Drugs 2011; 22:933-939.
2. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutionalbased review. J Clin Oncol 2010; 28:92-98.
3. Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010; 119: 621-631.
4. The Cancer Genome Atlas, Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
5. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic archi-tecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486:346-352.
6. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6:pl1:1-19.
7. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: anopen platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-404.
8. Temple R. Enrichment strategies. http://www.fda.gov/ucm/groups/fdagov- public/@fdagov-afda-orgs/documents/document/ucm303485.pdf. [Accessed 16 June 2013]
9. Callaway E. Cancer-gene testing ramps up. Nature 2010; 467:766-767.
10. Chapman PB, Hauschild A, Caroline R, et al. Improved survival with vemur-afenib in melanoma with BRAF V600E mutation. N Engl J Med 2010; 364:2507-2516.
11. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-365.
12. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-2394.
13. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
14. Food and Drug Administration. Targeted cancer therapies.; http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted. [Accessed 16 June 2013]
15. Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013; 39:313-320.
16. Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012; 10:161.
17. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16:121-130.
18. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010; 126:1121-1131.
19. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011; 16:404-414.
20. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954-2963.
21. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304:554.
22. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65:2554-2559.
23. Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120:2406-2413.
24. Yamnik RL, Digilova A, Davis DC, et al. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 2009; 284:6361-6369.
25. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyper-activation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68:9221-9230.
26. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12:395-402.
27. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-529.
28. O'Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzu-mab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BO-LERO-3). J Clin Oncol 2013; 31 (suppl); abstr 505.
29. Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 2013; 31 (suppl); abstr LBA509.
30. Fritsch C, Schnell C, Chatenay-Rivauday C, et al. NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anticancer agent. Cancer Res 2012; 72: abstr 3748.
31. Gonzalez-Angulo AM, Juric D, Argilés G, et al. Safety, pharmacokinetics, and preliminary activity of the a-specific PI3K inhibitor BYL719: results from the first-in-human study. J Clin Oncol 2013; 31 (suppl); abstr 2531.
32. Juric D, Krop I, Ramanathan RK, et al. GDC-0032, a beta isoform-sparing PI3K inhibitor: results of a first-in-human phase Ia dose escalation study. Proceedings of 2013 AACR Annual Meeting, abstract LB-64.
33. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3:264-279.
34. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10:116-129.
35. Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70:2085-2094.
36. Elbauomy Elsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9:R23.
37. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447:1087-1093.
38. Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013; 19:3693-3702.
39. Dienstmann R, Andrea F, Soria JC, et al. Significant antitumor activity of E-3810, a novel FGFR and VEGFR inhibitor, in patients with FGFR1 amplified breast cancer [abstract 3190]. Ann Oncol 2012; 29:ix116.
40. Wolf J, LoRusso PM, Camidge RD, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res 2012; 72 (suppl); abstr LB-122.
41. Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors a HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31:1997-2003.
42. Lee JW, Soung YH, Seo SH, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006; 12:57-61.
43. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013; 3:224-237.
44. Ross JS, Wang K, Sheehan CE, et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 2013; 19:2668-2676.
45. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010; 7:702-707.
46. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-921.
47. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-244.
48. Clark CC, Weitzel JN, O'Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012; 11:1948-1958.
49. Somlo G, Sparano JA, Cigler T, et al. ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial. J Clin Oncol 2012; 30 (suppl); abstr 1010.
50. Holstege H, Horlings H, Velds A, et al. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010; 10:654.
51. Manié E, Vincent-Salomon A, Lehmann-Che J, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009; 69:663-671.
52. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11:5175-5180.
53. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrando-mised study. Lancet Oncol 2011; 12:852-861.
54. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382-1392.
55. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 2013; 31 (Suppl); abstr 5505.
56. Musgrove EA, Caldon CE, Barraclough J, et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11:558-572.
57. Finn R, Crown J, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer. Cancer Res 2012; 72:S1-S6.
58. Andre F, Bachelot T, Campone M, et al. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): a prospective multicentric trial (SAFIR01). J Clin Oncol 2013; 31 (suppl); abstr 511.
59. Pusztai L, Mattair D, Ueno NT, et al. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): a pilot prospective tissue testing to guide clinical trial selection. J Clin Oncol 2013; 31 (suppl); abstr 532.
60. Bedard PL, Oza AM, Tsao M, et al., Princess Margaret Cancer Centre (PMCC). Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). J Clin Oncol 2013; 31 (suppl); abstr 11002.
61. Hollebecque A, Massard C, De Baere T, et al. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial-interim results. J Clin Oncol 2013; 31 (suppl); abstr2512.
62. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18:6373-6383.
63. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30:587-592.
64. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-892.
65. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013; 368:842-851.
66. Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199-1209.
67. Murtaza M, Dawson S-J, Tsui DWY, et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108-112.